Phospho-MUC1 (Tyr1229) Antibody

What is MUC1 and why is phosphorylation at Tyr1229 significant?

MUC1 (Mucin 1) is a membrane-bound glycoprotein belonging to the mucin family that plays essential roles in forming protective mucous barriers on epithelial surfaces and participating in intracellular signaling pathways. MUC1 is expressed on the apical surface of epithelial cells lining mucosal surfaces of many tissues including lung, breast, stomach, and pancreas . The protein undergoes proteolytic cleavage into alpha and beta subunits that form a heterodimeric complex, where the N-terminal alpha subunit functions in cell-adhesion while the C-terminal beta subunit is involved in cell signaling .

Phosphorylation at Tyr1229 is particularly significant because it occurs in the cytoplasmic domain of MUC1, which mediates interaction with various signaling molecules. This specific phosphorylation event regulates MUC1's involvement in signal transduction pathways that control cell growth, differentiation, and survival. Aberrant phosphorylation at this site may contribute to the oncogenic functions of MUC1 in various carcinomas, as overexpression, aberrant intracellular localization, and changes in glycosylation of MUC1 have been associated with multiple cancer types .

What are the applications of Phospho-MUC1 (Tyr1229) Antibody?

Phospho-MUC1 (Tyr1229) Antibody has multiple research applications:

This antibody specifically detects endogenous levels of MUC1 only when phosphorylated at Tyrosine 1229, making it valuable for studying phosphorylation-dependent functions and signaling mechanisms .

How should researchers prepare and store Phospho-MUC1 (Tyr1229) Antibody?

Proper handling and storage of Phospho-MUC1 (Tyr1229) Antibody is critical for maintaining its activity and specificity:

When working with the antibody, researchers should aliquot the stock solution upon first thaw to minimize freeze-thaw cycles. For most applications, the working concentration ranges from 0.5-5 μg/ml, though optimization is recommended for each specific experimental setup .

How can researchers differentiate between phosphorylated and non-phosphorylated forms of MUC1?

Distinguishing between phosphorylated and non-phosphorylated MUC1 is critical for studying its functional state. Several methodological approaches can be employed:

• Parallel detection using phospho-specific and total MUC1 antibodies on matched samples

• Phosphatase treatment controls to confirm phospho-specificity

• Use of phospho-peptide competition assays

The Phospho-MUC1 (Tyr1229) Antibody has been validated for specificity through sequential chromatography on phospho- and non-phospho-peptide affinity columns . This ensures the antibody detects only the phosphorylated form at Tyr1229.

For verification of specificity in experimental systems, researchers can:

• Perform dot blot analysis using phospho-peptide and non-phospho-peptide controls (similar to the validation shown for the Phospho-MUC1 (T1224) antibody)

• Use lambda phosphatase treatment of samples as a negative control

• Compare detection patterns with known phosphorylation-inducing treatments versus inhibitors

These approaches enable confident discrimination between the phosphorylated and non-phosphorylated forms of MUC1 in complex biological samples.

Western Blotting (WB) Protocol

• Sample preparation:

  • Lyse cells in RIPA buffer containing phosphatase inhibitors

  • Heat samples at 95°C for 5 minutes in reducing sample buffer

  • Load 20-50 μg protein per lane

• Electrophoresis and transfer:

  • Resolve proteins on 7.5% SDS-PAGE (MUC1 is ~170 kDa)

  • Transfer to PVDF membrane (recommended over nitrocellulose for phospho-proteins)

• Antibody incubation:

  • Block with 5% BSA in TBST (not milk, which contains phospho-proteins)

  • Incubate with Phospho-MUC1 (Tyr1229) antibody (1:1000 dilution) overnight at 4°C

  • Wash 3x with TBST

  • Incubate with HRP-conjugated secondary antibody (1:5000) for 1 hour at room temperature

  • Develop using enhanced chemiluminescence

• Controls:

  • Include HepG2 cell lysate as positive control

  • Consider including phosphatase-treated samples as negative controls

Immunofluorescence (IF) Protocol

• Cell preparation:

  • Culture cells on coverslips

  • Fix with 4% paraformaldehyde for 15 minutes at room temperature

  • Permeabilize with 0.1% Triton X-100 for 10 minutes

• Antibody staining:

  • Block with 1% BSA in PBS for 30 minutes

  • Incubate with Phospho-MUC1 (Tyr1229) antibody (1:100 dilution) overnight at 4°C

  • Wash 3x with PBS

  • Incubate with fluorophore-conjugated secondary antibody for 1 hour at room temperature

  • Counterstain nuclei with DAPI

  • Mount and image

• Controls and visualization:

  • Include cytoskeletal co-staining (e.g., phalloidin for actin filaments)

  • HepG2 cells serve as good positive controls

  • For better visualization, consider confocal microscopy to detect subcellular localization

Immunohistochemistry (IHC) Protocol

• Tissue preparation:

  • Use FFPE tissue sections (4-6 μm)

  • Deparaffinize and rehydrate sections

  • Perform heat-induced epitope retrieval in citrate buffer (pH 6.0)

• Antibody staining:

  • Block endogenous peroxidase with 3% H₂O₂

  • Block with 5% normal goat serum

  • Incubate with Phospho-MUC1 (Tyr1229) antibody (1:100-1:400 dilution) overnight at 4°C

  • Apply appropriate detection system (e.g., HRP-polymer)

  • Develop with DAB substrate

  • Counterstain with hematoxylin

• Controls:

  • Include human breast carcinoma as positive control

  • Include sections incubated with isotype control antibody as negative controls

How does phosphorylation at Tyr1229 affect MUC1's role in cell signaling pathways?

Phosphorylation of MUC1 at Tyr1229 acts as a molecular switch that regulates its participation in several critical signaling pathways:

• Receptor Tyrosine Kinase (RTK) Signaling: Tyr1229 phosphorylation creates docking sites for SH2 domain-containing proteins, facilitating interactions with growth factor receptors and their downstream signaling components.

• β-catenin Pathway: Phosphorylated MUC1 at Tyr1229 can enhance interaction with β-catenin, potentially influencing Wnt signaling pathway activation and nuclear translocation of β-catenin.

• STAT Pathway Integration: This phosphorylation event may facilitate MUC1's role in STAT transcription factor activation, affecting expression of genes involved in cell proliferation and survival.

• PI3K/Akt Pathway: Tyr1229 phosphorylation may contribute to activating the PI3K/Akt pathway through direct or indirect mechanisms, promoting cell survival signals.

The phosphorylation state of MUC1 at Tyr1229 is particularly relevant in cancer cells, where aberrant phosphorylation contributes to oncogenic signaling. This makes the Phospho-MUC1 (Tyr1229) Antibody an important tool for investigating these altered signaling dynamics in cancer research .

What approaches can be used to study the dynamic phosphorylation of MUC1 at Tyr1229?

Studying the dynamic phosphorylation of MUC1 at Tyr1229 requires temporal and contextual experimental designs:

• Time-course stimulation experiments:

  • Treat cells with growth factors, cytokines, or stress inducers

  • Collect samples at multiple time points (0, 5, 15, 30, 60 minutes)

  • Analyze changes in phosphorylation status using Western blotting with Phospho-MUC1 (Tyr1229) Antibody

  • Normalize to total MUC1 levels

• Phosphatase inhibitor studies:

  • Treat cells with various phosphatase inhibitors to identify regulators of MUC1 dephosphorylation

  • Monitor Tyr1229 phosphorylation status over time

• Kinase inhibitor panels:

  • Apply selective kinase inhibitors to identify specific kinases responsible for Tyr1229 phosphorylation

  • Quantify changes in phosphorylation levels

• Live-cell imaging approaches:

  • Develop FRET-based biosensors incorporating the region around Tyr1229

  • Monitor real-time phosphorylation dynamics in living cells

• Mass spectrometry-based phosphoproteomics:

  • Perform immunoprecipitation using total MUC1 antibodies

  • Analyze phosphorylation status by mass spectrometry

  • Validate findings using Phospho-MUC1 (Tyr1229) Antibody

These approaches can be combined with manipulation of cellular conditions (hypoxia, nutrient deprivation, cell density) to understand contextual regulation of MUC1 phosphorylation in physiological and pathological states.

How can researchers troubleshoot non-specific binding or weak signals?

When working with Phospho-MUC1 (Tyr1229) Antibody, researchers may encounter technical challenges. Here are methodological solutions:

For Western blotting applications specifically:

• Ensure MUC1 is properly resolved on gels (use 7.5% acrylamide for better separation of high molecular weight proteins)

• Optimize transfer conditions for large proteins (longer transfer time, reduced methanol in transfer buffer)

• Consider using gradient gels for better resolution

For immunostaining applications:

• Optimize fixation conditions (paraformaldehyde vs. methanol)

• Test different antigen retrieval methods

• Incubate in primary antibody solution longer at lower concentrations

How can researchers validate the specificity of Phospho-MUC1 (Tyr1229) antibody?

Validation of the Phospho-MUC1 (Tyr1229) Antibody's specificity is crucial for reliable research outcomes. Multiple complementary approaches should be employed:

• Peptide competition assay:

  • Pre-incubate the antibody with excess phospho-peptide (containing pTyr1229) or non-phospho-peptide control

  • Perform dot blot or Western blot analysis

  • Signal should be abolished by phospho-peptide but not by non-phospho-peptide

• Phosphatase treatment:

  • Divide cell lysate into two portions

  • Treat one portion with lambda phosphatase

  • Compare detection between treated and untreated samples

  • Signal should be reduced or eliminated in phosphatase-treated samples

• siRNA or CRISPR knockout:

  • Reduce MUC1 expression using siRNA or create MUC1 knockout

  • Both total and phospho-specific signals should be reduced in proportion

• Site-directed mutagenesis:

  • Generate Tyr1229 to Phe mutant constructs

  • Express in cell lines with low endogenous MUC1

  • Compare phospho-signal between wild-type and mutant

  • Mutant should show reduced or absent phospho-signal

• Kinase activation/inhibition:

  • Identify kinases that target Tyr1229

  • Activate or inhibit these kinases

  • Monitor corresponding changes in phosphorylation

These methodological approaches provide comprehensive validation of antibody specificity and ensure reliable interpretation of experimental results.

What are the implications of MUC1 Tyr1229 phosphorylation in cancer research?

MUC1 Tyr1229 phosphorylation has significant implications for cancer biology and represents an important target for cancer research:

• Biomarker potential:

  • Phosphorylation at Tyr1229 may serve as a prognostic or predictive biomarker

  • IHC analysis of patient samples using Phospho-MUC1 (Tyr1229) Antibody can help correlate phosphorylation status with clinical outcomes

  • Human breast carcinoma tissues show reactivity with this antibody, suggesting relevance in breast cancer

• Therapeutic target identification:

  • Understanding the kinases responsible for Tyr1229 phosphorylation may reveal novel therapeutic targets

  • Monitoring phosphorylation changes in response to experimental therapeutics

• Resistance mechanisms:

  • Altered MUC1 phosphorylation may contribute to therapy resistance

  • Studying phosphorylation dynamics in resistant vs. sensitive cell lines

• Metastasis research:

  • Investigating whether Tyr1229 phosphorylation correlates with metastatic potential

  • Analyzing changes in phosphorylation during epithelial-mesenchymal transition

Experimental approaches to study these implications include:

• Tissue microarray analysis of tumor samples using Phospho-MUC1 (Tyr1229) Antibody

• Correlation studies between phosphorylation status and patient outcomes

• In vitro and in vivo models manipulating Tyr1229 phosphorylation status

• Drug screening assays targeting pathways that regulate MUC1 phosphorylation

How does phosphorylation at Tyr1229 compare with other post-translational modifications of MUC1?

MUC1 undergoes multiple post-translational modifications (PTMs) that collectively determine its function. Understanding the relationship between Tyr1229 phosphorylation and other PTMs provides a more comprehensive picture of MUC1 regulation:

Research approaches to study PTM interplay include:

• Sequential immunoprecipitation with different PTM-specific antibodies

• Mass spectrometry analysis to identify co-occurring modifications

• Site-directed mutagenesis of multiple PTM sites

• Proximity ligation assays to detect proteins interacting with differentially modified MUC1

Understanding the hierarchy and interdependence of these modifications will provide deeper insights into MUC1 function in normal and pathological conditions.

What emerging technologies could enhance studies of MUC1 phosphorylation?

Several cutting-edge technologies hold promise for advancing our understanding of MUC1 Tyr1229 phosphorylation:

• Single-cell phosphoproteomics:

  • Analyze phosphorylation heterogeneity within tumor populations

  • Correlate with other cellular parameters

• Phospho-specific intrabodies:

  • Develop intracellular antibodies that specifically recognize phosphorylated Tyr1229

  • Monitor phosphorylation in living cells

• CRISPR-based phosphorylation reporters:

  • Insert luminescent or fluorescent tags into endogenous MUC1

  • Create phosphorylation-dependent conformational changes

• Spatial transcriptomics combined with phospho-proteomics:

  • Correlate Tyr1229 phosphorylation with spatial gene expression patterns

  • Map phosphorylation events to specific tumor microenvironments

• AI-driven analysis of phosphorylation networks:

  • Predict functional consequences of Tyr1229 phosphorylation

  • Identify novel therapeutic strategies targeting phosphorylation-dependent pathways

These emerging approaches will complement traditional antibody-based methods and provide more comprehensive and dynamic information about MUC1 phosphorylation in various biological contexts.

How can researchers integrate Phospho-MUC1 (Tyr1229) Antibody into multi-omics studies?

Integration of Phospho-MUC1 (Tyr1229) Antibody into multi-omics research frameworks can provide comprehensive insights:

• Combined phosphoproteomics and transcriptomics:

  • Correlate Tyr1229 phosphorylation status with gene expression profiles

  • Identify transcriptional programs associated with phosphorylation events

• Integration with kinome profiling:

  • Identify kinases that directly or indirectly regulate Tyr1229 phosphorylation

  • Map kinase networks affecting MUC1 function

• Metabolomics correlation:

  • Investigate how metabolic states affect MUC1 phosphorylation

  • Determine if Tyr1229 phosphorylation influences cellular metabolism

• Spatial biology approaches:

  • Use multiplexed immunofluorescence to localize phospho-MUC1 within tissue architecture

  • Correlate with markers of cellular states and other signaling molecules

• Patient-derived models:

  • Analyze phosphorylation in patient-derived xenografts or organoids

  • Correlate with drug responses and patient outcomes

By integrating Phospho-MUC1 (Tyr1229) Antibody-based analyses with these multi-omics approaches, researchers can develop a more holistic understanding of MUC1's role in health and disease, potentially leading to new diagnostic and therapeutic strategies.